VIR-7831

Phase 3Biologic

Eli Lilly

VIR-7831 is one of 19 biologic programs targeting COVID-19. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COVID-19Active, not recruiting

COVID-19Phase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

VIR-7831

Eli Lilly

Phase 3

5 2

COVID-19 Vaccine

Moderna

Preclinical

27 3

Singulair

AstraZeneca

Preclinical

1 4

Activella

Eli Lilly

Preclinical

—5

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 6

Nitrostat

VViatris Specialty LLC

Preclinical

1 7

SARS-COV-2 VACCINE

Moderna

Preclinical

2 8

Achromycin V

WWyeth-Lederle Vaccines

Statins

1 10

Disease-Modifying Anti-Rheumatic Drugs

Roche

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1/2Recruiting

COVID-19

NCT04746183

Clinical

Trials by Indication[1]

COVID-195 trials

ACTIV-3: Therapeutics for Inpatients With COVID-19

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT04501978·2,753 enrolled

AGILE (Early Phase Platform Trial for COVID-19)

Recruiting·UUniversity of Liverpool·Phase 1/2·NCT04746183·600 enrolled

A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT04634409·1,755 enrolled

Show 2 more trials

VIR-7831 for the Early Treatment of COVID-19 in Outpatients

Completed·VVir Biotechnology, Inc.·Phase 2/3·NCT04545060·1,057 enrolled

VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT05780281·367 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for VIR-7831. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VIR-7831 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VIR-7831. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Eli Lilly

VIR-7831

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

COVID-195 trials

References

Drug Info

Quick Facts

Related News